Medios AG, a leading provider of Specialty Pharma in Europe, has announced the appointment of Katrin Neuffer as Director Investor Relations & Communications, effective immediately. Neuffer, 49, will oversee the company's communications with investors, analysts, the media, and the public, succeeding Claudia Nickolaus, who has led the department and will now hand over leadership.
Neuffer brings approximately 20 years of experience in capital markets communications. She began her career at an investor relations agency and later served as Head of Investor Relations & Corporate Communications at SDAX-listed Wacker Neuson SE from 2007 to 2018, guiding the company from its IPO to its establishment as a consistently attractive investment. At Wacker Neuson, she also led the Strategy and Sustainability departments. Subsequently, she headed an international team of 20 as Vice President Investor Relations & Corporate Communications and Marketing at Exyte Group (formerly M+W Group), where she was responsible for preparing an IPO with a target market capitalization of more than EUR 2 billion. Since 2020, she has worked as an independent consultant, advising publicly listed companies on investor relations, IPO preparation, and crisis and restructuring communications.
Claudia Nickolaus played a key role in building and shaping Medios' investor relations activities, from financial reporting and ESG communications to the company's first Capital Markets Day in 2022. Prior to joining Medios, she held senior investor relations positions at publicly listed companies, including Merck KGaA.
Thomas Meier, CEO of Medios AG, commented, "With Katrin Neuffer, we are gaining a proven capital markets expert who has guided publicly listed companies through decisive phases of development, from IPOs to strategic repositioning. Her experience will help us reposition Medios in the capital markets and intensify our dialogue with investors, analysts, and the media. On behalf of the Company, I would like to express my sincere thanks to Claudia Nickolaus: Over many years, she shaped Medios' capital markets communications with tremendous dedication, a high level of professionalism, and personal reliability. She deserves our sincere gratitude for this."
The appointment comes as Medios prepares for several important events in the 2026 financial year, including the Half-Year Financial Report on August 12, participation in the Berenberg and Goldman Sachs 15th German Corporate Conference in Munich from September 21 to 23, the Medios Capital Markets Day on September 28/29, and the Quarterly Statement as of September 30 on November 10.
Medios AG is a leading provider of Specialty Pharma in Europe, with operations in Germany, the Netherlands, Belgium, and Spain. The company supports key partners in the supply chain with innovative solutions and intelligent services, focusing on pioneering individualized medicine to make the most innovative therapies available to everyone. Medios AG is Germany's first listed specialty pharmaceutical company, with shares listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index.
For more information on individualized medicine, visit https://app.medios.group/en/individualizedmedicine. The company's website is www.medios.group.
